Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma

被引：0
|
作者：
Alsina, Maria [1 ]
Fleitas-Kanonnikoff, Tania [2 ]
机构：
[1] Hosp Univ Navarra, Med Oncol Dept, Translat Med Oncol Invest Grp, Navarrabiomed IdiSNA, C-Irunlarrea 3, Pamplona 35008, Spain
[2] Hosp Clin Univ Valencia, Med Oncol Dept, INCLIVA, Valencia, Spain
来源：
MED | 2024年 / 5卷 / 09期
关键词：
CHEMOTHERAPY; PLACEBO;
D O I：
10.1016/j.medj.2024.05.016
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Immunotherapy has revolutionized the treatment landscape of esophageal squamous cell carcinoma. He et al. present the final results of the randomized phase 3 ESCORT-1st trial, confirming positive survival outcomes when adding the anti-PD1 inhibitor camrelizumab to first-line chemotherapy treatment in Chinese patients with esophageal squamous cell cancer.(1)
引用
收藏
页码：1038 / 1040
页数：3
相关论文
共 50 条
  • [1] Immune checkpoint inhibitors’ combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis
    Dianhe Li
    Ling Tang
    Jiazhu Hu
    Xiaolong Cao
    Yan He
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 933 - 939
  • [2] Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis
    Li, Dianhe
    Tang, Ling
    Hu, Jiazhu
    Cao, Xiaolong
    He, Yan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 933 - 939
  • [3] JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma
    Yamamoto, Shun
    Kato, Ken
    CANCER CELL, 2022, 40 (03) : 238 - 240
  • [4] Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma
    Zhang, Zhengfeng
    Yang, Lei
    Wang, Dazhen
    Ruan, Yuli
    Zhang, Jianji
    Zhao, Lu
    Yang, Liu
    Lou, Changjie
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [5] Comparative analysis of immune checkpoint inhibitors in first-line treatment of esophageal squamous cell carcinoma: a network meta-analysis
    Zhang, Yangfeng
    Li, Chunhui
    Du, Kunpeng
    Pengkhun, Nov
    Huang, Zijian
    Gong, Min
    Li, Yanyang
    Liu, Xiang
    Li, Lilin
    Wang, Duanyu
    Wang, Changqian
    Chen, Fengsheng
    Li, Jiqiang
    IMMUNOTHERAPY, 2023, 15 (10) : 737 - 750
  • [6] Advancements in the research of immune checkpoint inhibitors for the treatment of advanced esophageal squamous cell carcinoma
    Sun, Mengfei
    Yang, Pengjie
    Wang, Weisong
    Yu, Yongjun
    Yang, Dongdong
    Ping, Yaodong
    Zhu, Benben
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (05): : 1981 - 1998
  • [7] Rechallenge with immune checkpoint inhibitors for advanced esophageal squamous cell carcinoma
    Jin, Zhao
    Cao, Yanshuo
    Lu, Zhihao
    Liu, Chang
    Shen, Lin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 137
  • [8] First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features
    Fontes-Sousa, Mario
    Calvo, Emiliano
    CANCER TREATMENT REVIEWS, 2022, 105
  • [9] The Combining of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-Line Treatment for Advanced Stage Hepatocellular Carcinoma
    Lee, Shou-Wu
    Yang, Sheng-Shun
    Lien, Han-Chung
    Peng, Yen-Chun
    Tung, Chun-Fang
    Lee, Teng-Yu
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (16)
  • [10] Evidence on Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma
    Gao, Zhen
    Wang, Sichao
    Huang, Shujie
    JAMA ONCOLOGY, 2023, 9 (07) : 1004 - +
12345